Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
FibroGen, Inc.'s quarterly P/E stands at 0.1x.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -15.63 | 0.06 | — | 38.75 | 0.74 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 19.75 | 11.51 | 3.97 | 71.41 | — | 0.22 | 22.32 | 57.32 | 20.11 | 13.20 | 37.21 | 305.39 | 273.95 |
| — | +5210.9% | -82.2% | +24.6% | — | -98.4% | -40.0% | -81.2% | -92.7% | -97.3% | -82.0% | +165.8% | -44.6% | |
| P/B Ratio | — | 2.83 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | 0.42 | 72.36 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
FibroGen, Inc.'s operating margin was -502.9% in Q3 2025, up 391.2 pp QoQ and down 466.7 pp YoY. The trailing four-quarter average of -466.8% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 19.0% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.5% | 105.4% | 93.7% | 90.8% | 83.2% | 88.6% | -3156.5% | -128.0% | 80.1% | 89.4% | 87.1% | 90.3% | 85.7% |
| — | +19.0% | +103.0% | +170.9% | +3.9% | -1.0% | -3723.2% | -241.7% | -6.5% | +23.1% | +12.9% | +269.5% | +30.8% | |
| Operating Margin | -507.8% | -502.9% | -894.1% | -544.7% | 74.4% | -36.2% | -4650.1% | -193.9% | -199.7% | -158.2% | -198.7% | -210.4% | -192.5% |
| — | -1288.7% | +80.8% | -180.9% | +137.2% | +77.1% | -2240.6% | +7.8% | -3.7% | +73.4% | +24.3% | -103.2% | +76.5% | |
| Net Margin | -160.6% | 18646.5% | -564.0% | 169.4% | -14.6% | -36.9% | -1557.5% | -129.8% | -207.2% | -158.5% | -197.8% | -212.1% | -192.6% |
| — | +50670.5% | +63.8% | +230.4% | +93.0% | +76.7% | -687.3% | +38.8% | -7.6% | +72.8% | +18.8% | -104.1% | +76.2% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | 1147.5% | — | — | — | — | — | — | — | — | — | — | -295.5% |
| — | — | — | — | — | — | — | — | — | — | — | — | -532.7% | |
| ROA | -14.9% | 127.4% | -4.4% | 2.4% | 7.5% | -6.1% | -4.7% | -8.3% | -12.7% | -13.0% | -16.6% | -13.4% | -10.9% |
| — | +2178.5% | +6.1% | +129.3% | +159.0% | +53.0% | +71.7% | +37.5% | -17.2% | +7.8% | -64.2% | -60.6% | +34.2% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 189.0% YoY to 3.71x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 1.11 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.47 | 3.71 | 1.04 | 2.02 | 1.47 | 1.28 | 1.41 | 1.41 | 1.52 | 1.74 | 2.12 | 1.69 | 1.80 |
| — | +189.0% | -26.1% | +43.1% | -3.2% | -26.2% | -33.5% | -16.3% | -15.4% | -7.6% | -2.2% | -17.7% | -14.3% | |
| Quick Ratio | 1.45 | 3.60 | 1.02 | 1.98 | 1.45 | 1.16 | 1.24 | 1.27 | 1.33 | 1.54 | 1.91 | 1.52 | 1.65 |
| — | +211.1% | -17.9% | +55.4% | +8.9% | -25.0% | -35.1% | -16.3% | -19.4% | -10.4% | -4.4% | -19.2% | -15.8% | |
| Interest Coverage | -18.24 | -2.60 | -6.00 | -6.61 | — | -3.36 | -24.84 | -23.51 | -10.69 | -12.64 | -28.69 | -32.08 | -59.12 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonFibroGen, Inc.'s current P/E is -15.6x. The average P/E over the last 3 quarters is 13.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
FibroGen, Inc.'s current operating margin is -507.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking FibroGen, Inc.'s business trajectory between earnings reports.